Episódios

  • Heart Transplant for Advanced Heart Failure
    Oct 12 2026

    Heart transplant for patients with advanced heart failure can lead to improved survival and quality of life. Author JoAnne Lindenfeld, MD, of Vanderbilt University joins JAMA Associate Editor David Simel, MD, MHS, to discuss indications, transplant evaluation, management after transplant, long-term complications, and survival.

    Related Content:

    • Heart Transplant for Advanced Heart Failure
    Exibir mais Exibir menos
    23 minutos
  • Narcolepsy: A Review
    Oct 5 2026

    Narcolepsy is a chronic neurologic disorder that causes severe daytime sleepiness and impaired quality of life. Author Tom Scammell, MD, of Harvard Medical School joins JAMA Deputy Editor Karen Lasser, MD, MPH, to discuss the etiology, clinical presentation, diagnostic evaluation, and treatment of narcolepsy.

    Related Content:

    • Narcolepsy
    • The Orexin System—A Key Component of Sleep Regulatory Networks and Involvement in Narcolepsy
    Exibir mais Exibir menos
    21 minutos
  • Influenza, RSV, and COVID-19 Vaccines: Effectiveness, Safety, and Trust in 2026
    Sep 30 2026

    Respiratory virus vaccine effectiveness and safety for influenza, RSV, and COVID-19 are reviewed, including new evidence, risks, and recommendations. JAMA Deputy Editor Preeti Malani, MD, MSJ, speaks with Rochelle Walensky, MD, MPH, professor of medicine at Harvard Medical School and former CDC Director, about vaccine data, public trust, and the 2026 respiratory virus season.

    Related Content:

    • Respiratory Season Virus Vaccines
    • RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season
    • Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
    • COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
    Exibir mais Exibir menos
    14 minutos
  • Vaccines for Cancer Treatment
    Sep 21 2026

    Cancer vaccines stimulate immune cells to recognize proteins or mutations found on or within cancer cells, facilitating destruction of cancer cells. Several vaccines are approved and others are in development for cancer treatment. Author Nora Disis, MD, JAMA Deputy Editor and Editor in Chief of JAMA Oncology, discusses cancer vaccines and more with JAMA Deputy Editor Mary McDermott, MD.

    Related Content:

    • Vaccines for Cancer
    Exibir mais Exibir menos
    20 minutos
  • Idiopathic Normal Pressure Hydrocephalus: Diagnosis and Treatment
    Sep 14 2026

    Idiopathic normal pressure hydrocephalus (iNPH) affects approximately 1% to 4% of adults aged 65 years and older and is associated with gait impairment, cognitive decline, and urinary dysfunction. Author Mark G. Luciano, MD, PhD, from Johns Hopkins University, discusses this and more with JAMA Deputy Editor Kristin Walter, MD, MS.

    Related Content:

    • Idiopathic Normal Pressure Hydrocephalus
    Exibir mais Exibir menos
    19 minutos
  • Rheumatoid Arthritis
    Sep 10 2026

    Rheumatoid arthritis can affect any synovial joint and cause irreversible damage, but early diagnosis and treatment with DMARDs can reduce inflammation and lower the risk of joint destruction. JAMA Associate Editor David Simel, MD, MHS, is joined by review coauthor Josef Smolen, MD, to discuss this topic.

    Related Content:

    • Rheumatoid Arthritis in Adults
    Exibir mais Exibir menos
    23 minutos
  • An Overview of Postural Orthostatic Tachycardia Syndrome (POTS)
    Aug 24 2026

    POTS is a chronic autonomic disorder characterized by excessive orthostatic tachycardia and multisystem symptoms that affects an estimated 0.1% to 1% of the US population. Author Satish Raj, MD, MSCI, of University of Calgary Cumming School of Medicine joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss current evidence about the pathophysiology, diagnosis, and management of POTS.

    Related Content:

    • Postural Orthostatic Tachycardia Syndrome (POTS)
    Exibir mais Exibir menos
    29 minutos
  • Medication Treatments for Alcohol Use Disorder
    Aug 19 2026

    Naltrexone, acamprosate, disulfiram, and topiramate are effective but underused medications for treatment of alcohol use disorder. Author Stephen Holt, MD, MS, of Yale School of Medicine joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss first-line pharmacotherapy for alcohol use disorder and important safety, efficacy, and hospital initiation considerations.

    Related Content:

    • Medications for Alcohol Use Disorder
    Exibir mais Exibir menos
    20 minutos